Navigation Links
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
Date:4/29/2009

- Primary Endpoint met With a Significant Reduction in Relapse Rate

- Secondary Endpoints met Including MRI Measures, Proportion of Patients Relapse-Free and Disability Progression

- Submission for Registration of Cladribine Tablets Planned for mid-2009

SEATTLE and GENEVA, April 30 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, announced today detailed results of the two-year (96-week) placebo-controlled CLARITY(1) Phase III trial using Cladribine Tablets (Merck Serono's proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS). The results of the pivotal trial show that annual short-course treatment with Cladribine Tablets led to a significant reduction in the rate of clinical relapses, disability progression and brain lesions, as well as a significant increase in the proportion of patients who remained relapse-free. The data were presented today for the first time, as a late-breaking oral presentation at the 61st Annual Meeting of the American Academy of Neurology (AAN) in Seattle, WA.

"All primary and secondary endpoints of the CLARITY study were statistically significant and demonstrate that annual short-course treatment with Cladribine Tablets in this study was effective across multiple important clinical and MRI efficacy measures," said Dr. Gavin Giovannoni, principal investigator of the study, Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, United Kingdom.

"We are very pleased with the successful outcome of the CLARITY study," said Elmar Schnee, President of Merck Serono. "This is an exciting development in multiple sclerosis clinical research, and represents an important step towards delivering an oral therapy to people living with this condition."

The results from both Cladribine Tablets treatment groups in the study d
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
4. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
9. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
10. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
11. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Based ... closure market, Frost & Sullivan recognises Incisive Surgical ... for Customer Value Leadership. Incisive Surgical,s uniquely-designed, innovative ... technology that eliminates the need for patients to ... and staple removal  that may result in increased ...
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix ... focused on developing and commercializing therapeutic products for ... infectious diseases, announces the amendment and restatement of ... preferred stock and related warrants, as well as ... stock and warrant financing, to remove anti-dilution, price ...
(Date:9/16/2014)... , Sept. 16, 2014  DNAtrix, Inc., experts ... first patient was treated with the company,s lead ... interferon in a randomized, multicenter, open-label Phase Ib ... "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists ... initiation of our randomized Phase Ib study of ...
Breaking Medicine Technology:Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... HARTLAND, Wis., Aug. 30, 2011 H&P Industries, Inc., ... hiring of Eamonn Vize to fill the Chief Operating ... 20 years of experience in the Pharmaceutical and Biotechnology ... provide his knowledge of Pharmaceutical Operations and Validations to ...
... , a leading supplier of embedded technologies, products, and ... embedded computers to a medical original equipment ... of the six-month contract is about 1.5M USD. ... will allow the customer to meet market demand and ...
Cached Medicine Technology:Eurotech Awarded 1.5M USD Contract to Supply Embedded Computers for Medical Application 2
(Date:9/16/2014)... 16, 2014 CarePoint Health is ... Leigh Montes, MD, has joined our expanded Bariatric ... Hospital. Our system welcomes Dr. Montes to the ... surgical weight loss center, helps patients achieve long-term ... surgery procedures, including Gastric Sleeve, Gastric Bypass, LAP-BAND ...
(Date:9/16/2014)... HealthDay Reporter MONDAY, Sept. 15, 2014 ... can delay a man,s onset of age-related high blood pressure ... pressure naturally increases as people grow older and their arteries ... don,t start drifting toward high blood pressure until their mid-50s. ... early signs of high blood pressure in their mid-40s, researchers ...
(Date:9/16/2014)... discoveries everyday, but that doesn,t mean the findings are ... example, the neonatal mortality rate is 10 times higher ... that applying an inexpensive topical solution of chlorhexidine to ... rate by 24 percent, many Indian parents did not ... not that we don,t have solutions to solve major ...
(Date:9/16/2014)... The Columbia University College of Dental Medicine ... in Diversity (HEED) award from INSIGHT Into Diversity ... higher education. As a recipient of the annual ... universities that demonstrate an outstanding commitment to diversity ... other recipients in INSIGHT Into Diversity magazine,s November ...
(Date:9/16/2014)... Size is relative, especially to people who tend to ... University Medical Center in the US found that seven ... weighs. People of normal weight make this mistake much ... tend to misjudge their children,s size, as youngsters misjudge ... now at Weill-Cornell Medical College, in a study in ...
Breaking Medicine News(10 mins):Health News:Top Bariatric Surgeon Joins CarePoint Health 2Health News:Top Bariatric Surgeon Joins CarePoint Health 3Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Pairing social networks with social motives to close the science gap 2Health News:Pairing social networks with social motives to close the science gap 3Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Poor body size judgement can lead to increased tolerance of obesity 2
... , MONDAY, March 21 (HealthDay News) -- A woman,s use ... risk of respiratory problems in her children, according to a ... use of birth control pills may increase the risk of ... said the authors of the new study. The researchers ...
... MONDAY, March 21 (HealthDay News) -- While the majority of ... generally satisfied years later, almost 40 percent are saddled with ... removed, a small, new Belgian study reveals. The finding ... the University of California, San Francisco that suggested gastric bypass ...
... Rockville, Md., March 21, 2011 As part of ... Pharmacopeial Convention (USP) is working with the Food and ... (CHPA) to update quality standards for widely used medicines ... an ambitious, long-term effort to assess written (or documentary) ...
... Health Sciences University is enrolling patients in a federally funded ... progression of kidney disease. "The question is, if you ... said Dr. Laura Mulloy, Chief of the GHSU Section of ... Intervention Trial, or SPRINT, funded by the National Institutes of ...
... change the balance of bacteria that naturally live in the ... Brain, Behavior, and Immunity . "These bacteria ... the immune response," said lead researcher Michael Bailey. ... number of gut microorganisms, according to scientists from The Ohio ...
... March, 2011 Alcohol use during pregnancy is common ... and development of exposed offspring. Despite warnings from the ... contemplating pregnancy, a recent survey by the National Birth ... drank alcohol at some time during their pregnancy, with ...
Cached Medicine News:Health News:Moms' Use of 'the Pill' Won't Raise Kids' Asthma Risk: Study 2Health News:40% of Gastric Banding Patients Have Complications 2Health News:40% of Gastric Banding Patients Have Complications 3Health News:40% of Gastric Banding Patients Have Complications 4Health News:Quality standards for widely used medicines strengthened 2Health News:Quality standards for widely used medicines strengthened 3Health News:Study examines whether lower blood pressure reduces kidney disease progression 2Health News:Adolescent offspring of women who drank alcohol during first trimester 2
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet....
Medicine Products: